-
韩国美学探索者金素恩 让自然之美在时间中沉淀
当人们对于美的关注逐渐回归理性,相比追求快速改变,越来越多人开始重新思考:什么才是真正属于自己的美? 或许,美并不是不断靠近某一种标准,而是在理解自己、尊重自己
-
World First: KFSH Jeddah's Single-Session Stem Cell Protocol Sets a New Global Standard
World First: KFSH Jeddah's Single-Session Stem Cell Protocol Sets a New Global Standard Balancing Donor Safety and Treatment Efficiency JEDDAH, Kingd
-
森马全球首座时尚创新空间SEMIR STUDIO,于新嘉中心盛大开业
6月30日,国民生活方式品牌森马开启全新概念店SEMIR STUDIO,重塑都市青年生活美学地标。该空间集设计灵感孵化、青年生活方式探索、时尚与创意碰撞于一体,正式落
-
From plastic waste to chocolate wrappers: LYB and Mondelez collaborate on Marabou flexible packaging
ROTTERDAM, Netherlands, July 07, 2026 (GLOBE NEWSWIRE) -- Global chemical leader LyondellBasell (NYSE: LYB) today announced an innovative flexible pac
-
Hesab Selects Movement as Exclusive Stablecoin Settlement Layer for Its Global Self-Custody Bank
The collaboration represents a landmark deployment of Movement's stablecoin settlement infrastructure, giving Hesab's users across 160+ countries true
-
United Kingdom to Acquire All Remaining Non-Regional Shares of IDB Invest's Capital Increase
WASHINGTON, July 07, 2026 (GLOBE NEWSWIRE) -- The United Kingdom is moving to acquire all remaining non-regional unsubscribed shares in IDB Invest’s
-
United Kingdom to Acquire All Remaining Non-Regional Shares of IDB Invest's Capital Increase
WASHINGTON, July 07, 2026 (GLOBE NEWSWIRE) -- The United Kingdom is moving to acquire all remaining non-regional unsubscribed shares in IDB Invest’s
-
United Kingdom to Acquire All Remaining Non-Regional Shares of IDB Invest's Capital Increase
WASHINGTON, July 07, 2026 (GLOBE NEWSWIRE) -- The United Kingdom is moving to acquire all remaining non-regional unsubscribed shares in IDB Invest’s
-
Access Advance 欢迎新许可方加入视频分发专利池
Access Advance LLC 今天宣布Sharp、M&K Holdings、Tagivan 和其他 9 家专利权人已于 2026 年上半年加入视频分发专利池(VDP 池)。这些专利权人拥有大量视频编解码
-
Jensen Hughes收购HiLT,进一步扩大东南亚业务版图
消防与生命安全、安保及基于风险的工程与咨询领域的全球领导者Jensen Hughes今日宣布,已收购新加坡领先的消防工程公司HiLT Pte. Ltd. (HiLT)。此次收购进一步巩固
-
Agenus在ESMO GI 2026大会上公布BOT+BAL的里程碑式数据,结果显示,对于无活动性肝转移的难治性MSS转移性结直肠癌,三年总生存率达33%
• 123名患者入组满员的1b期队列显示,中位总生存期为21.2个月,三年总生存率为33%,且生存曲线在两年后出现平台期 • 该数据针对的是既往接受过重度预治疗的患者群体,
-
Orion与Shilpa Medicare深化合作,共同开发并供应欧洲市场纳武利尤单抗生物类似药
Shilpa Medicare Limited宣布,其全资子公司Shilpa Biologicals Private Limited已与Orion Corporation签署一项合作开发及供应协议,双方将共同开发并供应静脉注射(IV
